nirsevimab
Sign in to saveAlso known as MED-18897, MEDI8897
Nirsevimab, sold under the brand name Beyfortus, is a human recombinant monoclonal antibody with activity against respiratory syncytial virus (RSV). It is a respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor that is designed to bind to the fusion protein on the surface of the RSV virus.
Clinical Trials
24 registered- PHASE3COMPLETEDStudy of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of LifeSanofi Pasteur, a Sanofi Company · NCT05437510
- RECRUITINGPrevention Strategy for Respiratory Syncytial Virus (RSV) Infections in Infants in FranceAssistance Publique - Hôpitaux de Paris · NCT06881953
- COMPLETEDEffectiveness of Nirsevimab in Children Hospitalised With RSV BronchiolitisCentre Hospitalier Intercommunal Creteil · NCT06030505
- RECRUITINGEvaluation of the Effect of Nirsevimab on Hospitalizations Due to RSV Infection in Infants Under One Year of Age.Meyer Children's Hospital IRCCS · NCT06856967
- NOT_YET_RECRUITINGThe Effectiveness of Early Immunisation With Nirsevimab on Preschool Wheezing in France, Based on an Analysis of Data From the French Health System Database.Hospices Civils de Lyon · NCT07317141
- COMPLETEDReal-World Effectiveness of Nirsevimab Against RSV-Related and All-Cause Respiratory Tract Infections in Chinese InfantsHan Tongyan · NCT07382219
~7 min read
Article
10 sectionsContents
- Medical uses
- Adverse effects
- Pharmacology
- Mechanism of action
- History
- Society and culture
- Legal status
- Research
- See also
- References
Nirsevimab, sold under the brand name Beyfortus, is a human recombinant monoclonal antibody with activity against respiratory syncytial virus (RSV). It is a respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor that is designed to bind to the fusion protein on the surface of the RSV virus.
The most common side effects are rash, fever and injection site reactions (such as redness, swelling and pain where the injection is given).